CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.100
-0.070 (-3.23%)
At close: Aug 7, 2025, 4:00 PM
2.090
-0.010 (-0.48%)
Pre-market: Aug 8, 2025, 8:32 AM EDT
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $18.66M in the quarter ending June 30, 2025, a decrease of -25.71%. This brings the company's revenue in the last twelve months to $141.10M, up 18.01% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm)
$141.10M
Revenue Growth
+18.01%
P/S Ratio
1.44
Revenue / Employee
$1,166,116
Employees
121
Market Cap
330.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CTMX News
- 16 hours ago - CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 2 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - GlobeNewsWire
- 3 months ago - CytomX Therapeutics: Doubling Overnight On Phase 1 Data - Seeking Alpha
- 3 months ago - CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript) - Seeking Alpha
- 3 months ago - Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
- 3 months ago - CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - GlobeNewsWire